Alto Neuroscience, Inc. SEC filings ANRO
Alto Neuroscience, Inc. has 196 filings in SEC EDGAR's recent list, going back to Nov 22, 2023. Its latest annual report, Form ARS, was filed on Mar 26, 2026 for the period ended Dec 31, 2025. The latest quarterly report (Form 10-Q) was filed on Aug 12, 2026, covering the quarter ended Jun 30, 2026. The most recent current report (Form 8-K) was filed on Aug 27, 2026 (officer or director change). The company's fiscal year ends on December 31.
| Form | Description | Filed | Period |
|---|---|---|---|
| 8-K |
Current report
Officer or director change
|
Aug 27, 2026 | Aug 26, 2026 |
| 10-Q | Quarterly report | Aug 12, 2026 | Jun 30, 2026 |
| 8-K |
Current report
Results of operations
|
Aug 12, 2026 | Aug 12, 2026 |
| 8-K |
Current report
Material agreement
|
Jul 14, 2026 | Jul 13, 2026 |
| 424B5 | Prospectus supplement | Jul 14, 2026 | — |
| 8-K |
Current report
Results of operations, Other events
|
Jul 13, 2026 | Jul 13, 2026 |
| 8-K |
Current report
Officer or director change
|
May 28, 2026 | May 27, 2026 |
| 8-K |
Current report
Officer or director change, Shareholder vote results
|
May 13, 2026 | May 12, 2026 |
| 10-Q | Quarterly report | May 13, 2026 | Mar 31, 2026 |
| 8-K |
Current report
Results of operations
|
May 13, 2026 | May 13, 2026 |
| EFFECT | Filing | Apr 20, 2026 | — |
| CORRESP | Letter to the SEC | Apr 17, 2026 | — |
| UPLOAD | Letter from the SEC | Apr 16, 2026 | — |
| S-3 | Shelf registration | Apr 10, 2026 | — |
| 8-K |
Current report
Other events
|
Apr 1, 2026 | Apr 1, 2026 |
| ARS | Annual report to shareholders | Mar 26, 2026 | Dec 31, 2025 |
| DEFA14A | Additional proxy material | Mar 26, 2026 | — |
| DEF 14A | Proxy statement | Mar 26, 2026 | May 12, 2026 |
| 8-K |
Current report
Material agreement, Unregistered share sale, Other events
|
Mar 16, 2026 | Mar 16, 2026 |
| S-8 | Employee stock plan registration | Mar 16, 2026 | — |
| 10-K | Annual report | Mar 16, 2026 | Dec 31, 2025 |
| 8-K |
Current report
Results of operations
|
Mar 16, 2026 | Mar 16, 2026 |
| EFFECT | Filing | Dec 10, 2025 | — |
| CORRESP | Letter to the SEC | Dec 8, 2025 | — |
| S-3 | Shelf registration | Nov 28, 2025 | — |
| 10-Q | Quarterly report | Nov 12, 2025 | Sep 30, 2025 |
| 8-K |
Current report
Results of operations
|
Nov 12, 2025 | Nov 12, 2025 |
| D | Filing | Oct 27, 2025 | — |
| 8-K |
Current report
Material agreement, Agreement ended, Unregistered share sale, Other events
|
Oct 20, 2025 | Oct 19, 2025 |
| 10-Q | Quarterly report | Aug 13, 2025 | Jun 30, 2025 |
| 8-K |
Current report
Results of operations, Officer or director change
|
Aug 13, 2025 | Aug 12, 2025 |
| 8-K |
Current report
Officer or director change
|
Jul 8, 2025 | Jul 3, 2025 |
| 8-K |
Current report
Other events
|
Jun 26, 2025 | Jun 26, 2025 |
| 8-K |
Current report
Material agreement, Unregistered share sale, Other events
|
Jun 3, 2025 | May 31, 2025 |
| 10-Q | Quarterly report | May 14, 2025 | Mar 31, 2025 |
| 8-K |
Current report
Results of operations, Shareholder vote results
|
May 14, 2025 | May 13, 2025 |
| DEFR14A | Filing | May 9, 2025 | — |
| ARS | Annual report to shareholders | Apr 1, 2025 | Dec 31, 2024 |
| DEFA14A | Additional proxy material | Apr 1, 2025 | — |
| DEF 14A | Proxy statement | Apr 1, 2025 | May 13, 2025 |
| S-8 | Employee stock plan registration | Mar 20, 2025 | — |
| 10-K | Annual report | Mar 20, 2025 | Dec 31, 2024 |
| 8-K |
Current report
Results of operations, Officer or director change
|
Mar 20, 2025 | Mar 17, 2025 |
| 8-K |
Current report
Other events
|
Feb 12, 2025 | Feb 12, 2025 |
| EFFECT | Filing | Feb 11, 2025 | — |
| CORRESP | Letter to the SEC | Feb 7, 2025 | — |
| UPLOAD | Letter from the SEC | Feb 7, 2025 | — |
| 8-K |
Current report
Material agreement, Results of operations
|
Feb 3, 2025 | Feb 3, 2025 |
| S-3 | Shelf registration | Feb 3, 2025 | — |
| 8-K |
Current report
Material agreement, New debt, Unregistered share sale
|
Jan 16, 2025 | Jan 13, 2025 |
| 10-Q | Quarterly report | Nov 12, 2024 | Sep 30, 2024 |
| 8-K |
Current report
Results of operations
|
Nov 12, 2024 | Nov 12, 2024 |
| 8-K |
Current report
Other events
|
Oct 22, 2024 | Oct 22, 2024 |
| 10-Q | Quarterly report | Aug 13, 2024 | Jun 30, 2024 |
| 8-K |
Current report
Results of operations
|
Aug 13, 2024 | Aug 13, 2024 |
| 8-K |
Current report
Material agreement, New debt, Unregistered share sale
|
Jul 29, 2024 | Jul 24, 2024 |
| 8-K |
Current report
Officer or director change
|
May 21, 2024 | May 21, 2024 |
| 10-Q | Quarterly report | May 14, 2024 | Mar 31, 2024 |
| 8-K |
Current report
Results of operations
|
May 14, 2024 | May 14, 2024 |
| 10-K | Annual report | Mar 21, 2024 | Dec 31, 2023 |
| 8-K |
Current report
Results of operations
|
Mar 21, 2024 | Mar 21, 2024 |
| 8-K |
Current report
Officer or director change
|
Mar 11, 2024 | Mar 8, 2024 |
| S-8 | Employee stock plan registration | Feb 6, 2024 | — |
| 8-K |
Current report
Bylaw or fiscal year change
|
Feb 6, 2024 | Feb 6, 2024 |
| 424B4 | Prospectus | Feb 5, 2024 | — |
| SEC STAFF LETTER | Filing | Feb 2, 2024 | — |
| EFFECT | Filing | Feb 1, 2024 | — |
| S-1MEF | Filing | Feb 1, 2024 | — |
| CERT | Nyse certification | Jan 30, 2024 | — |
| 8-A12B | Filing | Jan 30, 2024 | — |
| CORRESP | Letter to the SEC | Jan 30, 2024 | — |
| CORRESP | Letter to the SEC | Jan 30, 2024 | — |
| S-1/A | Amended registration statement | Jan 29, 2024 | — |
| S-1/A | Amended registration statement | Jan 29, 2024 | — |
| CORRESP | Letter to the SEC | Jan 25, 2024 | — |
| CORRESP | Letter to the SEC | Jan 24, 2024 | — |
| UPLOAD | Letter from the SEC | Jan 23, 2024 | — |
| CORRESP | Letter to the SEC | Jan 19, 2024 | — |
| CORRESP | Letter to the SEC | Jan 12, 2024 | — |
| S-1 | Registration statement | Jan 12, 2024 | — |
| SEC STAFF LETTER | Filing | Jan 9, 2024 | — |
| UPLOAD | Letter from the SEC | Jan 9, 2024 | — |
| DRSLTR | Filing | Dec 28, 2023 | — |
| DRS/A | Filing | Dec 28, 2023 | — |
| UPLOAD | Letter from the SEC | Dec 19, 2023 | — |
| D | Filing | Nov 27, 2023 | — |
| D | Filing | Nov 27, 2023 | — |
| D | Filing | Nov 27, 2023 | — |
| D | Filing | Nov 27, 2023 | — |
| DRS | Filing | Nov 22, 2023 | — |
Showing 90 filings. Main filings leave out insider and ownership forms such as Form 4; choose a type above to see them. Each form opens on SEC.gov. Older filings are on SEC EDGAR.
New to this? Read What Are SEC Filings? 10-K, 10-Q, 8-K and Other Forms Explained.
Company profile
- Industry
- Pharmaceutical Preparations (SIC 2834)
- Listed as
- ANRO (NYSE)
- Fiscal year ends
- December 31
- Incorporated in
- DE
- Headquarters
- Mountain View, CA
- SEC filer status
- , Emerging growth company
- SEC CIK
- 1999480
Other Pharmaceutical Preparations companies
- ELI LILLY & Co LLY
- Johnson & Johnson JNJ
- AbbVie Inc. ABBV
- Merck & Co., Inc. MRK
- Novartis AG NVS
- Astrazeneca PLC AZN
- Abbott Laboratories ABT
- Novo Nordisk A S NVO
Source: SEC EDGAR filings. This is company-reported data, not investment advice.